Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by Red5Lukeon Jul 31, 2018 1:42pm
116 Views
Post# 28392639

RE:RE:RE:RE:8 of the last 9 months bearish

RE:RE:RE:RE:8 of the last 9 months bearishHopefully their China visit was fruitful.  At a minimum you would hope they could announce they met with Wanbang and picked up their $500K USD cheque.  And maybe have some details on the clinical trial? 

The upside could be more news on the 1067 front but I don't think anybody is getting their hopes up on that one. 


From Dec 2017 NR....  "In light of the challenges faced, we have accelerated the clinical development strategy. A successful clinical trial will yield compelling scientific data which will further increase the value and marketability of the compound. "

I would just be happy to find out an update on the TFC-1067 trials?  Have they even started?  It has been 8 months since this statement was made so I don't see the "accelerated" portion of the strategy being executed.  
Bullboard Posts